GREENLIT VENTURES INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that GREENLIT VENTURES INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $34.5K | Jun 29, 2020 |
| FY2019 | Dec 31, 2018 | $5.9K | Jun 29, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2020 | $32.0K | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $34.5K | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $15.9K | Jun 29, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2020 | $23.8K | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $19.5K | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $13.4K | Jun 29, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($48.5K) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($227.5K) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($63.6K) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($55.5K) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($67.6K) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($105.4K) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($59.5K) | Mar 15, 2021 |
| FY2020 | Dec 31, 2018 | ($127.1K) | Mar 15, 2021 |
| FY2018 | Dec 31, 2017 | ($13.6K) | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | ($3.3K) | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($57.3K) | Mar 8, 2024 |
| FY2023 | Dec 31, 2022 | ($54.0K) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($67.6K) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($105.4K) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($64.0K) | Mar 15, 2021 |
| FY2020 | Dec 31, 2018 | ($137.9K) | Mar 15, 2021 |
| FY2018 | Dec 31, 2017 | ($13.6K) | Mar 28, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Mar 8, 2024 |
| FY2023 | Dec 31, 2022 | $11.0K | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 30, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($11.9K) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($50.3K) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($62.9K) | Mar 15, 2021 |
| FY2020 | Dec 31, 2018 | ($84.9K) | Mar 15, 2021 |
| FY2018 | Dec 31, 2017 | ($17.3K) | Mar 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $66.2K | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $153.9K | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $249.1K | Jun 29, 2020 |
| FY2018 | Dec 31, 2017 | $6.0K | Mar 28, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $237.4K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $188.9K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $154.1K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $90.5K | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $35.1K | Mar 30, 2023 |
| FY2020 | Dec 31, 2020 | $136.0K | Mar 15, 2021 |
| FY2020 | Dec 31, 2019 | $118.4K | Mar 15, 2021 |
| FY2020 | Dec 31, 2018 | $154.1K | Mar 15, 2021 |
| FY2018 | Dec 31, 2017 | $19.1K | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $1.0K | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($237.4K) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($188.9K) | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | ($154.1K) | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | ($90.5K) | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | ($35.1K) | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | ($69.9K) | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $35.6K | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $95.0K | Mar 15, 2021 |
| FY2019 | Dec 31, 2017 | ($13.1K) | Jun 29, 2020 |
| FY2018 | Dec 31, 2016 | ($1.0K) | Mar 28, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($771.7K) | Apr 15, 2026 |
| FY2025 | Sep 30, 2025 | ($771.7K) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($723.2K) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($495.7K) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($432.1K) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($376.6K) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($309.0K) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($203.6K) | Mar 15, 2021 |
| FY2020 | Dec 31, 2018 | ($144.1K) | Mar 15, 2021 |
| FY2018 | Dec 31, 2017 | ($17.0K) | Mar 28, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2020 | $11.9K | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $57.7K | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $244.1K | Jun 29, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 27, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4.08M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 4.08M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 229,579 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 6.73M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | 6.73M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 6.73M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 6.73M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | 6.73M | Jun 29, 2020 |
| FY2018 | Dec 31, 2017 | 6.50M | Mar 28, 2019 |
| FY2018 | Nov 19, 2017 | 20.00M | Mar 28, 2019 |